p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
Open Access
- 22 November 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 15 (1) , 101276
Abstract
No abstract availableKeywords
Funding Information
- Amgen
- Merck Sharp and Dohme United Kingdom
- Merck
- Bristol-Myers Squibb
- Broad Institute
- Novartis
- Eli Lilly and Company
- Roche
- Pfizer
- Meso Scale Diagnostics
- Boehringer Ingelheim
- Bayer
- AstraZeneca
This publication has 26 references indexed in Scilit:
- Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)Journal of Thoracic Oncology, 2015
- Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer2015
- New CODIS core loci allele frequencies for 96,400 Brazilian individualsForensic Science International: Genetics, 2014
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Annals of Oncology, 2013
- Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomasCancer, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- The International Epidemiology of Lung Cancer: Geographical Distribution and Secular TrendsJournal of Thoracic Oncology, 2008
- STRBase: a short tandem repeat DNA database for the human identity testing communityNucleic Acids Research, 2001
- Mutational Activation of the K-rasOncogeneNew England Journal of Medicine, 1987